University of Liege in Liege, Belgium have discovered miR-146a a new molecule that can serve as a potential biomarker for peripartum cardiomyopathy. Peripartum cardiomyopathy (PPCM) is a deterioration in cardiac function that occurs in pregnant women during the last month or in the months following their pregnancy.
Struman and colleagues found that expression of miR-146a was induced by the nursing hormone prolactin. MiR-146a expression promoted vascular damage and was increased in a mouse model of PPCM. Conversely, loss of miR-146a in mice prevented PPCM. Importantly, miR-146a expression was elevated in the serum of pregnant women who developed PPCM, suggesting that serum miR-146a levels could predict which patients are at risk for the disease. In a companion commentary, Richard Kitsis of Albert Einstein College of Medicine in New York, discusses the potential implications of this work for the identification and treatment of PPCM.
You May Also Like